There is a quiet, rhythmic hum of the HVAC system in the background of our office today, which somehow makes reporting on the CDC’s latest internal friction feel even more stark. Misryoum editorial desk noted that a critical report highlighting how well Covid vaccines reduce hospitalization rates has been shelved—or at least paused—by the agency’s acting director. It’s a move that has left many wondering about the intersection of policy and data.
Dr. Jay Bhattacharya, currently helming the National Institutes of Health and serving as acting CDC director, reportedly pumped the brakes on the findings. Misryoum reporting suggests he took issue with the observational methodology. You have to wonder, though—is it just the method, or the message? The study was originally destined for the Morbidity and Mortality Weekly Report in March, but now it’s sitting in limbo.
Actually, the situation is a bit more tangled than a simple disagreement on stats. Misryoum analysis indicates that a near-identical study focusing on flu vaccines, which used the exact same approach to track patient outcomes in emergency rooms, was published by the same journal just a week earlier without a hitch. It feels inconsistent, but maybe that’s just how things go when leadership changes hands at such a high level.
Department of Health and Human Services spokesperson Emily G. Hilliard mentioned that it is “routine” for leadership to flag concerns about methodology. Whether or not that’s standard practice for political appointees to weigh in on independent research outside their specific lane of expertise is… well, she didn’t exactly clarify that part. The silence on that question is pretty loud.
This delay arrives amidst a broader shift in federal health policy under Robert F. Kennedy Jr. Since his appointment, we’ve seen the complete overhaul of the advisory committee on immunizations and the removal of longstanding vaccine recommendations. The committee even walked back advice for newborns regarding hepatitis B, which is a major, major shift in public health strategy. It’s hard to keep track of all these moving parts, or maybe that’s the point—to keep us all spinning.
Even the FDA hasn’t been immune to the turbulence, initially blocking a new Moderna flu vaccine application before reversing course after a February sit-down. The atmosphere in D.C. health agencies is thick with tension right now. We are watching to see if this vaccine report ever sees the light of day, or if it just becomes another footnote in a year of massive, messy bureaucratic pivots. I’m not sure what to expect next, honestly.